Synthetic biology is transforming the development of human and animal therapeutics.  The unreliable, costly discovery and development process for new medicines is being replaced by the engineering of biology at the genetic, molecular, and cellular level.  Intrexon's ability to regulate complex gene programs and cellular systems at commercial scale is at the forefront of this revolution by applying the principles of science, engineering, and computational bioinformatics with proprietary technologies to design new therapies for humans and animals. 

Through our Better DNA® approach, Intrexon is currently enabling collaborators to develop targeted gene therapy applications and novel solutions within oncology, rare skin disorders, active pharmaceutical ingredients, ocular diseases, human infertility, infectious diseases, and animal health.